Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with Compugen’s COM701 in the treatment of advanced solid tumors. This collaboration will evaluate the combination of COM701, an anti-PVRIG antibody under investigation by Compugen, with Opdivo, a programmed death-1 (PD-1) […]